News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–13
Matches
13
Sources here
2
Companies here
1
Search results Stored financial headlines

Active search

13 matching headlines

Ticker or company: N1BI34Main company stories
Clear
Latest

finance.yahoo.com Market update

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed …

Main company 🇧🇷 Brazil
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, with INGREZZA, CRENESSITY, and newly acquired VYKAT XR leading record sales. The company also …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Neurocrine Biosciences appointed a new Chief Business Officer and three Senior Vice Presidents to its senior leadership team. The moves come as the company …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Neurocrine Biosciences (NBIX) stock is in focus after the company reported second quarter 2026 revenue of US$959 million and net income of US$144.4 …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth

Neurocrine Biosciences, Inc. NBIX highlighted the continued expansion of its commercial portfolio during its second-quarter 2026 earnings call, with management emphasizing growth from INGREZZA, CRENESSITY and the newly acquired VYKAT XR. The company also outlined upcoming clinical catalysts and its strategy to diversify beyond …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
PR Newswire Deals and strategy Main company 🇧🇷 Brazil

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine Biosciences Inc (NBIX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

This article first appeared on GuruFocus. Total Revenue: Over $950 million in Q2 2026, representing nearly 40% year-over-year growth. Non-GAAP EPS: $2.85 per share for the second quarter. INGREZZA Net Sales: $716 million in Q2, up 15% year-over-year, driven by record new patient additions. …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) reported $959 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 39.5%. EPS of $2.85 for the same period compares to $1.06 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $901.54 …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Wall Street analysts expect Neurocrine Biosciences (NBIX) to post quarterly earnings of $2.26 per share in its upcoming report, which indicates a year-over-year increase of 113.2%. Revenues are expected to be $901.54 million, up 31.1% from the year-ago quarter. The consensus EPS estimate for …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Neurocrine Biosciences stock has delivered an 83.9% return over the past five years. With the shares recently closing at US$172.69, the valuation picture now looks more like …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Neurocrine Biosciences (NasdaqGS:NBIX) has appointed Samir Siddhanti as Chief Business Officer. Siddhanti will also join the company's executive Management Committee. The new role is focused …

N1BI34 main company
Sharemaestro market context Trend signal active 52 weeks +16.3% N1BI34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context